Induction of pregnant women onto opioid-agonist maintenance medication: An analysis of withdrawal symptoms and study retention

Drug and Alcohol Dependence

Volumn 132, Issue 1-2, 2013, Pages 329-334

  Holbrook, Amber M ^a   Jones, Hendree E ^b,c   Heil, Sarah H ^d,e   Martin, Peter R ^f,g   Stine, Susan M ^h   Fischer, Gabriele ⁱ   Coyle, Mara G ^j   Kaltenbach, Karol ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b RTI INTERNATIONAL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF VERMONT   (United States)

^f VANDERBILT UNIVERSITY   (United States)

^g VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j BROWN UNIVERSITY   (United States)

more..

Author keywords

Buprenorphine induction; CINA; Methodone induction; Opioid dependence; Opioid withdrawal; Pregnancy

Indexed keywords

BUPRENORPHINE; METHADONE; MORPHINE SULFATE; OPIATE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PREGNANT WOMAN; PRIORITY JOURNAL; SCORING SYSTEM; WITHDRAWAL SYNDROME;

BUPRENORPHINE INDUCTION; CINA; METHODONE INDUCTION; OPIOID DEPENDENCE; OPIOID WITHDRAWAL; PREGNANCY;

ADULT; ANALYSIS OF VARIANCE; BUPRENORPHINE; CONFIDENCE INTERVALS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; EDUCATIONAL STATUS; ETHNIC GROUPS; FEMALE; HUMANS; LINEAR MODELS; METHADONE; MORPHINE; NARCOTICS; PATIENT DROPOUTS; PREGNANCY; PREGNANCY COMPLICATIONS; SOCIOECONOMIC FACTORS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84881667140     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.02.031     Document Type: Article

References (27)

1. Auriacombe M., Fatséas M., Dubernet J., Daulouède J.P., Tignol J. French field experience with buprenorphine. Am. J. Addict. 2004, 13(Suppl. 1):S17-S28.
2. Center for Substance Abuse Treatment Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40 2004, DHHS Publication No. (SMA) 04-3939. Substance Abuse and Mental Health Services Administration, Rockville, MD.
3. DiPaula B.A., Schwartz R., Montoya I.D., Barrett D., Tang C. Heroin detoxification with buprenorphine on an inpatient psychiatric unit. J. Subst. Abuse Treat. 2002, 23:163-169.
4. Fajemirokun-Odudeyi O., Sinha C., Tutty S., Pairaudeau P., Armstrong D., Phillips T., Lindow S.W. Pregnancy outcome in women who use opiates. Eur. J. Obstet. Gynecol. Reprod. Biol. 2006, 126:170-175.
5. Fischer G., Gombas W., Eder H., Jagsch R., Peternell A., Stuhlinger G., Pezawas L., Aschauer H.N., Kasper S. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 1999, 94:1337-1347.
6. Fischer G., Johnson R.E., Jagsh R., Peternell A., Weninger M., Langer M., Aschauer H.N. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 2000, 95:239-244.
7. Gaalema D.E., Scott T.L., Heil S.H., Coyle M.G., Kaltenbach K., Badger G.J., Arria A., Stine S.M., Martin P.R., Jones H.E. Differences in the profile of neonatal abstinence syndrome signs in methadone vs. buprenorphine exposed neonates. Addiction 2012, 107(Suppl. 1):53-62.
8. Gordon A.Q., Lopatko O., Somogyi A., Foster D., Wjite J. (R)- and (S)-methadone concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy. Br. J. Clin. Pharmacol. 2010, 70:895-902.
9. Gowing L., Ali R., White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst. Rev. 2009, CD002025.
10. Kaltenbach K., Berghella V., Finnegan L. Opioid dependence during pregnancy: effects and management. Obstet. Gynecol. Clin. North Am. 1998, 25:139-151.
11. Kandall S.R., Doberczak T.M., Jantunen M., Stein J. The methadone-maintained pregnancy. Clin. Perinatol. 1999, 26:173-183.
12. Jasinski D.R., Oevnick J.S., Griffith J.D. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch. Gen. Psychiatr. 1978, 35:501-516.
13. Johnson R.E., Jones H.E., Jasinski D.R., Svikis D.S., Haug N.A., Jansson L.M., Kissin W.B., Alpan G., Lantz M.E., Cone E.J., Wilkins D.G., Golden A.S., Huggins G.R., Lester B.M. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend. 2001, 63:97-103.
14. Jones H.E., Fischer G., Heil S.H., Heil Kaltenbach K., Martin P.R., Coyle M.G., Selby P., Stine S.M., O'Grady K.E., Arria A.M. Maternal opioid treatment: human experimental research (MOTHER)-approach, issues, and lessons learned. Addiction 2012, 107(Suppl. 1):28-35.
15. Jones H.E., Johnson R.E., Jasinski D.R., Milo L. Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone. Drug Alcohol Depend. 2005, 78:33-38.
16. Jones H.E., Kaltenbach K., Heil S., Stine S., Coyle M., Arria A., O'Grady K., Selby P., Martin P.R., Fischer G. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N. Engl. J. Med. 2010, 363:2320-2331.
17. Jones H.E., O'Grady K.E., Malfi D., Tuten M. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am. J. Addict. 2008, 17:372-386.
18. Mattick R.P., Ali R., White J., O'Brien S., Wolk S., Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind with 405 opioid-dependent patients. Addiction 2003, 98:441-452.
19. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. 2008, 3:CD002209.
20. McCarthy J.J., Leamon M.L., Parr M.S., Anania B.A. High dose methadone maintenance in pregnancy: maternal and neonatal outcomes. Am. J. Obstet. Gynecol. 2005, 193:606-610.
21. Megarbane B., Hreiche R., Pirnay S., Marie N., Baud F.J. Does high-dose buprenorphine cause respiratory depression? Possible mechanisms and therapeutic consequences. Toxicol. Rev. 2006, 25:79-85.
22. Nanovskaya T.N., Deshmukh S., Brooks M., Ahmed M. Transplacental transfer and metabolism of buprenorphine. J. Pharmacol. Exp. Ther. 2002, 3:26-33.
23. National Institutes of Health Consensus Development Panel Effective medical treatment of opiate addiction. National Consensus Development Panel on effective treatment of opiate addiction. J. Am. Med. Assoc. 1998, 280:1938-1943.
24. Peachy J.E., Lei H. Assessment of opioid dependence with naloxone. Br. J. Addict. 1988, 83:193-201.
25. Petitjean S., Stohler R., Deglon J.J., Livoti S., Waldvogel D., Uehlinger C., Ladewig D. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend. 2001, 62:97-104.
26. Whitley S.D., Sohler N.L., Kunins H.V., Giovanniello A., Li X., Sacajiu G., Cunningham C.O. Factors associated with complicated buprenorphine inductions. J. Subst. Abuse Treat. 2010, 39:51-57.
27. Winklbaur B., Kopf N., Ebner N., Jung E., Thau K., Fischer G. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction 2008, 103:1429-1440.